M&A / successionCH· 1mo ago
Swiss HBM Healthcare plans to sell Swixx Biopharma for $1.7 billion | AKM EN
HBM Healthcare is exploring options for Swixx Biopharma, including a potential sale valued at about 1.5 billion Swiss francs ($1.7B), with Jefferies and Centerview Partners advising.
Intent
WATCH· 54intent / 100
▸ why this score▾ score breakdown
- default: P(contract_to_capital_90d) · p=0.30 × w=3.0+0.9
- default: OON discount · × 0.75-0.3
- Final score (ambiguity-dampened) · default=54+54
- V2 winner: default · default=54+0
Go-to-market brief
Daily 5 RWA signals
Five signals in your inbox each morning. Email only.
Free. The daily 5 lands at 07:00 UTC, nothing else. One-click unsubscribe in every email.